An affordable growth strategy seeks companies that combine meaningful earnings and revenue expansion with a valuation that does not require perfection. The approach is meant to avoid the two extremes: expensive momentum names with stretched multiples and cheap stocks whose growth prospects are weak. One stock that currently surfaces from this approach is ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY).
Growth Profile
Alnylam’s ChartMill growth rating is 8 out of 10, reflecting strong historical results as well as favorable forward estimates. The company is coming off a period of rapid expansion, and the projected trajectory remains well above industry norms.
- Earnings per share grew 354.25% over the past year.
- Revenue increased 65.19% in the last year, with average annual revenue growth of 49.77% over prior years.
- EPS is expected to grow roughly 61.72% per year over the coming years.
- Revenue is projected to grow 25.54% annually on average, still strong even if slower than the recent pace.
That kind of growth is central to the affordable growth screen. The screen does not simply look for any growing company; it looks for growth that is substantial enough to support future earnings power.
Valuation Picture
The valuation rating comes in at 7 out of 10, which is the other half of the affordability test. On an absolute basis, some of Alnylam’s multiples are not cheap, but relative to its biotech peers and its own growth rate, the stock screens as reasonable.
- Trailing price-to-earnings is 32.73, below the industry average of 43.07 but above the S&P 500’s 25.48.
- Forward price-to-earnings is 19.04, cheaper than the industry’s 31.52 and roughly in line with the S&P 500’s 21.30.
- The price-to-forward-earnings multiple is well below the sector median.
- Enterprise value to EBITDA and price to free cash flow both screen as favorable relative to industry peers.
- A low PEG ratio suggests that expected growth compensates for the earnings multiple.
This is where the affordable growth case is strongest. Alnylam’s forward earnings multiple is far below the biotech peer group, while its growth expectations are far above it. Investors who want to see the underlying data behind these scores can review the detailed report on this fundamental analysis page.
Profitability and Financial Health
The screen also includes minimum thresholds for profitability and financial health, so that growth is not bought at the expense of company quality. Alnylam’s profitability rating is 6 out of 10, while its health rating is 5 out of 10. Neither score is exceptional, but both clear the screen’s standards.
- Return on assets is 11.25%, and return on equity is 53.68%.
- Return on invested capital is 15.72%.
- Operating margin is 17.54%, with a profit margin of 13.46% and a gross margin of 80.83%.
- Altman-Z score is 4.28, suggesting no immediate bankruptcy risk.
- Current ratio is 3.13, and the quick ratio is 3.06, indicating strong short-term liquidity.
There are some offsetting concerns. The debt-to-equity ratio is 2.31, which points to meaningful reliance on external financing. Alnylam also reported negative earnings in four of the past five years, although it posted positive earnings over the past year. The company does not pay a dividend, which is common for a biotech in this stage but still matters for income-focused investors.
Why This Combination Matters
Valuation and growth alone can be misleading. A low multiple can be a value trap if growth deteriorates, while a high-growth story can be fully priced in before the earnings arrive. The profitability and health checks add context. Alnylam’s strong margins and above-average return on invested capital give its growth narrative more credibility than a broad screen would otherwise show.
The balance between growth, valuation, and quality is exactly what the affordable growth methodology is designed to capture. Alnylam has the growth metrics to justify attention, the relative valuation to suggest that the market has not priced in every upside scenario, and enough profitability and financial stability to reduce some of the risk associated with faster-growing names.
Investors who want to find more stocks that pass the same combination of growth, valuation, profitability, and health filters can run the [affordable growth screen]([[SCREEN_L
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation
An affordable growth strategy seeks companies that combine meaningful earnings and revenue expansion with a valuation that does not require perfection. The approach is meant to avoid the two extremes: expensive momentum names with stretched multiples and cheap stocks whose growth prospects are weak. One stock that currently surfaces from this approach is ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY).
Growth Profile
Alnylam’s ChartMill growth rating is 8 out of 10, reflecting strong historical results as well as favorable forward estimates. The company is coming off a period of rapid expansion, and the projected trajectory remains well above industry norms.
That kind of growth is central to the affordable growth screen. The screen does not simply look for any growing company; it looks for growth that is substantial enough to support future earnings power.
Valuation Picture
The valuation rating comes in at 7 out of 10, which is the other half of the affordability test. On an absolute basis, some of Alnylam’s multiples are not cheap, but relative to its biotech peers and its own growth rate, the stock screens as reasonable.
This is where the affordable growth case is strongest. Alnylam’s forward earnings multiple is far below the biotech peer group, while its growth expectations are far above it. Investors who want to see the underlying data behind these scores can review the detailed report on this fundamental analysis page.
Profitability and Financial Health
The screen also includes minimum thresholds for profitability and financial health, so that growth is not bought at the expense of company quality. Alnylam’s profitability rating is 6 out of 10, while its health rating is 5 out of 10. Neither score is exceptional, but both clear the screen’s standards.
There are some offsetting concerns. The debt-to-equity ratio is 2.31, which points to meaningful reliance on external financing. Alnylam also reported negative earnings in four of the past five years, although it posted positive earnings over the past year. The company does not pay a dividend, which is common for a biotech in this stage but still matters for income-focused investors.
Why This Combination Matters
Valuation and growth alone can be misleading. A low multiple can be a value trap if growth deteriorates, while a high-growth story can be fully priced in before the earnings arrive. The profitability and health checks add context. Alnylam’s strong margins and above-average return on invested capital give its growth narrative more credibility than a broad screen would otherwise show.
The balance between growth, valuation, and quality is exactly what the affordable growth methodology is designed to capture. Alnylam has the growth metrics to justify attention, the relative valuation to suggest that the market has not priced in every upside scenario, and enough profitability and financial stability to reduce some of the risk associated with faster-growing names.
Investors who want to find more stocks that pass the same combination of growth, valuation, profitability, and health filters can run the [affordable growth screen]([[SCREEN_L
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »